Organogenesis Holdings (ORGO) Cash & Equivalents (2015 - 2026)

Organogenesis Holdings' Cash & Equivalents history runs 11 years deep, the most recent figure standing at $91.4 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 16.9% year-over-year to $91.4 million in Q1 2026; TTM through Mar 2026 was $91.4 million, a 16.9% decrease from a year earlier, with the FY2025 full-year figure at $93.7 million, down 30.9% from the prior year.
• Cash & Equivalents eased to $91.4 million in Q1 2026 per ORGO's latest filing, from $93.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $135.6 million in Q4 2024 and bottomed at $63.7 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $94.3 million (2024), against an average of $97.1 million.
• Across the five-year window, Cash & Equivalents jumped 30.56% in 2024 and sank 32.43% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $102.5 million in 2022, then climbed by 1.33% to $103.8 million in 2023, then soared by 30.56% to $135.6 million in 2024, then tumbled by 30.9% to $93.7 million in 2025, then slipped by 2.46% to $91.4 million in 2026.
• Per Business Quant, the three latest ORGO Cash & Equivalents figures stand at $91.4 million (Q1 2026), $93.7 million (Q4 2025), and $63.7 million (Q3 2025).